AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.
Tag Archive for: ACI-24.060
AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.